Nestlé Health Science and Enterome are jointly creating Microbiome Diagnostics Partners (MDP), which aims to lead the development and commercialization of innovative microbiome-based diagnostics with potential to transform therapeutic approaches across a broad spectrum of challenging health conditions, including inflammatory bowel diseases and liver diseases. The partnership follows Nestlé Health Science’s initial investment announced in April 2016.
MDP’s initial focus will be accelerating Enterome’s diagnostic programs, which include IBD 110 for the assessment and management of mucosal healing and MET210 for NASH (non-alcoholic steatohepatitis). Current standard of care for these conditions include invasive procedures such as endoscopy and biopsies, rather than a non-invasive stool/serum combined diagnostic tests that will be developed by MDP. Future innovation efforts will leverage advanced microbial and serum-based metabolic technologies developed respectively at Enterome and Nestlé Health Science’s diagnostics arm Prometheus Laboratories.
Commenting upon the move Greg Behar, CEO of Nestlé Health Science, said, “Microbiome Diagnostics Partners is equipped to lead diagnostic discovery in the microbiome field, opening the door to innovative therapeutic approaches combining diagnostics, nutritional therapies and therapeutics. Mastering the microbiome is an important facet of our strategy to advance the therapeutic role of nutrition. We also see new opportunities for personalized nutrition both for the healthy population and for patients. The two initial programs have great potential to become differentiated diagnostics.”
Pierre Belichard, CEO of Enterome, said, “The formation of Microbiome Diagnostics Partners is an important milestone for Enterome, as it brings together powerful and complementary technologies and capabilities to enable the creation of a new generation of diagnostic and companion diagnostic products. The MDP joint venture will leverage Enterome’s microbiome-based platforms in diagnostic areas, while Enterome will continue to focus on their application for the discovery of novel small molecule therapeutics.”